key: cord-0742669-6k9262pd authors: Filbin, Michael R.; Mehta, Arnav; Schneider, Alexis M.; Kays, Kyle R.; Guess, Jamey R.; Gentili, Matteo; Fenyves, Bánk G.; Charland, Nicole C.; Gonye, Anna L.K.; Gushterova, Irena; Khanna, Hargun K.; LaSalle, Thomas J.; Lavin-Parsons, Kendall M.; Lilly, Brendan M.; Lodenstein, Carl L.; Manakongtreecheep, Kasidet; Margolin, Justin D.; McKaig, Brenna N.; Rojas-Lopez, Maricarmen; Russo, Brian C.; Sharma, Nihaarika; Tantivit, Jessica; Thomas, Molly F.; Gerszten, Robert E.; Heimberg, Graham S.; Hoover, Paul J.; Lieb, David J.; Lin, Brian; Ngo, Debby; Pelka, Karin; Reyes, Miguel; Smillie, Christopher S.; Waghray, Avinash; Wood, Thomas E.; Zajac, Amanda S.; Jennings, Lori L.; Grundberg, Ida; Bhattacharyya, Roby P.; Parry, Blair Alden; Villani, Alexandra-Chloé; Sade-Feldman, Moshe; Hacohen, Nir; Goldberg, Marcia B. title: Plasma proteomics reveals tissue-specific cell death and mediators of cell-cell interactions in severe COVID-19 patients date: 2020-11-03 journal: bioRxiv DOI: 10.1101/2020.11.02.365536 sha: bf1ffbf84f91375e1e1993d8e80d34b8185a55a3 doc_id: 742669 cord_uid: 6k9262pd COVID-19 has caused over 1 million deaths globally, yet the cellular mechanisms underlying severe disease remain poorly understood. By analyzing several thousand plasma proteins in 306 COVID-19 patients and 78 symptomatic controls over serial timepoints using two complementary approaches, we uncover COVID-19 host immune and non-immune proteins not previously linked to this disease. Integration of plasma proteomics with nine published scRNAseq datasets shows that SARS-CoV-2 infection upregulates monocyte/macrophage, plasmablast, and T cell effector proteins. By comparing patients who died to severely ill patients who survived, we identify dynamic immunomodulatory and tissue-associated proteins associated with survival, providing insights into which host responses are beneficial and which are detrimental to survival. We identify intracellular death signatures from specific tissues and cell types, and by associating these with angiotensin converting enzyme 2 (ACE2) expression, we map tissue damage associated with severe disease and propose which damage results from direct viral infection rather than from indirect effects of illness. We find that disease severity in lung tissue is driven by myeloid cell phenotypes and cell-cell interactions with lung epithelial cells and T cells. Based on these results, we propose a model of immune and epithelial cell interactions that drive cell-type specific and tissue-specific damage in severe COVID-19. Acuity max resulted in largely overlapping sets of differentially expressed proteins with the Olink platform (hypergeometric test p=0.002, 69% of severity-associated proteins overlapped with those identified by Olink data) (Table S13, online methods). To derive organ-specific expression signatures, we leveraged gene expression data from the Genotype-Tissue Expression (GTEx) 33 portal (online methods) and verified the cell type of origin of each protein in a given signature within each tissue of interest, reassuringly finding that our derived signatures were expressed primarily in epithelial cells (Extended Data Fig. 14) . We then identified plasma proteins in our datasets that overlapped with these gene sets (Table S14) , looking specifically at proteins that are intracellular and thus are likely to leak into circulation as a result of tissue damage ( Fig. 3A; Extended Data Fig. 15A ). When possible, we validated our organ-specific signatures ( Table S14) against lab values measured clinically; this showed significant correlations of our heart signature with clinical troponin levels (R=0.52, p < 0.001), our liver signature with clinical ALT (R=0.6, p < 0.001) and AST (R=0.46, p < 0.001), our skeletal muscle signature with clinical CPK (R=0.6, p < 0.001), and negative correlations between our kidney signature and GFR (R=-0.36, p < 0.001) ( Fig. 3B; Extended Data Fig. 16 ). In patients with severe COVID-19 (A1, A2), heart, lung, and skeletal muscle intracellular protein signatures were elevated in plasma as early as D0 and this elevation persisted to D7 (Fig. 3A) . Consistent with this, elevated heart and skeletal muscle protein signatures at D0 portended poor overall survival, but this was not the case for lung, kidney, liver, and pancreas signatures ( Fig. 3C; Table S15 ). Interestingly, in severely ill patients, liver and pancreas intracellular protein signatures were decreased in the plasma at D3 and D7 (Fig. 3A) ; over the same timeframe, liver-specific secreted proteins were decreased, whereas pancreas-specific secreted proteins were increased (Extended Data Fig. 17 ). Together these results suggest that illness drives damage to the heart and lung and that this damage signature can be detected early in the circulation upon hospital presentation. We mapped intracellular severity-associated plasma proteins to specific tissues and cell types using scRNAseq datasets (Extended Data Figs. 18, 19, online methods). Analysis of scRNAseq datasets from healthy tissues revealed that plasma proteins at D0 (Table S5 ) are expressed in macrophage subsets and epithelial cells, with notably increased relative expression in proximal tubule cells in the kidney, hepatocytes in the liver, and stellate, ductal, and acinar cells in the pancreas (Extended Data Fig. 19 ). By analyzing expression of intracellular severity-associated proteins (Table S5) in the more physiologically-relevant context of single cells of bronchoalveolar lavage (BAL) fluid from COVID-19 infected patients 34 , we found distinct clusters of proteins expressed within lung epithelial cells and within T cells, with little expression in tissueassociated myeloid or B cells (Fig. 3D) . These tissue-associated patterns highlight the distinct contributions to the plasma proteome of cell types in the circulation and those in tissue ( Fig. 3D; Extended Data Fig. 11 ). Within lung epithelial cells, expression of severity-associated proteins correlated with ACE2 expression (R=0.49, p = 0.04), but not with TMPRSS2 expression (Fig. 3F; Extended Data Fig. 15B ), which suggests that the increased levels of these proteins in plasma results from SARS-CoV-2 infection and death of these cells and that other proteases may be redundant with TMPRSS2 for priming during viral entry. In contrast, heart cell-type plasma signatures did not correlate with ACE2 expression (Extended Data Fig. 18B) , suggesting that heart damage is largely an indirect effect of the disease process, putatively due to the inflammatory response. The implications of the observed correlation with TMPRSS2 expression on cells (R=0.62, p < 0.001; Fig. 3F ) is unclear. Similarly, intracellular plasma signatures from cell subsets that do not express ACE2 or TMPRSS2 (Fig. 3D) likely results from bystander cell death. Of note, unlike in the blood, a larger subset of severity-associated plasma proteins is expressed in effector and cytotoxic CD8+ T cells and NK cells located within the lung (Fig. 3D) . Together, our data suggest that death of lung epithelial cells may be a key driver of the pathology of severe disease, and this may be detected from signals in the circulating proteome. To gain insights into inflammatory pathways activated in severe disease and given the likely role in disease of elevated levels of circulating proteins, we looked for enrichment of these pathways among plasma proteins that are normally secreted or membrane-bound. Among the D0 severity-associated proteome, NF-kB signaling, NK cell activation, IL6 and IL10 signaling, and Th1 and Th2 activation were significantly enriched (Extended Data Fig. 17A ). To identify cellular mechanisms regulated by this subset of proteins, we analyzed ligand-receptor interactions 35,36 using the BAL fluid cell dataset from COVID-19-infected patients 34 ( Fig. 4A; online methods). From D0 to D3, there was a dramatic increase in the number of predicted ligand-receptor interactions (Fig. 4A) , predominantly represented by ligand-receptor interactions occurring in lung epithelial cells, T cells, and mast cells (Fig. 4B) . Most dramatic were changes in mast cells, driven by their interactions with other mast cells, CD4+ and CD8+ T cell subsets, and epithelial progenitors (Fig. 4B) . Consistent with this, the mast cell function marker tryptase was differentially expressed between severe and non-severe patients and over time (Extended Data Fig. 20) . Whereas lung epithelial cells showed predicted ligand-receptor interactions with other epithelial cells, monocytes and macrophages, and CD8+ T cells, and NK cells, pronounced COVID-19 severity and temporal changes were observed in proteins mediating interactions between epithelial progenitors and cytotoxic/effector CD8+ T cells or NK cells (Fig. 4B-F) . To better understand the specific pathways mediating disease severity, we constructed mappings of key ligand-receptor relationships of cells in BAL fluid with plasma severity-associated ligands at D0 and D3 (Extended Data Fig. 21) . Pairings of ligands from lung epithelial cells with receptors on other lung epithelial cells were involved in alveolar maintenance and 9 protection, growth factor signaling, and tissue regeneration (HGF-MET, TGFA-EGFR, DKK1-LRP6, KITLG-KIT, semaphorin-PLXNA receptors, among others; Fig. 4C ). Moreover, several T cell activating and exhaustion signals originated from lung epithelial cells, mediated by PVR signaling through TIGIT and CD96 as early as D0, and eventual activation of IL7 and IL18 pathways at D3 (Fig. 4C) . To better understand the pathways affecting lung epithelial cells, we focused on the receptors expressed in these cells, specifically those that have ligands that were severity-associated in our model (Fig. 4D) . A correlation matrix using plasma expression levels of these ligands identified coregulated groups of proteins that act on lung epithelial cells. Amongst these were clear protein modules for regeneration and growth factor signaling (module 1: EGF, TGFB1, DKK1, VEGFA; module 2: BMP6, HGF, RSPO3, RSPO1) and for IL6 pathway signaling (OSM, LIF, IL6) (Fig. 4D) . Amongst the severity-associated ligands expressed on monocytes/macrophages are many known to be associated with death in COVID-19 (IL8, CXCL8, CCL2, CCL7, CCL8, and CCL20; Figs. 2D, 4E). We found several previously poorly characterized monocyte/macrophage ligand-receptor interactions with lung epithelial cells and other myeloid cells, most apparent at D3, that may be involved in driving later-stage damage and regulating phagocytosis (e.g. TGFB1-ITGB6 and ITGB8, SPP1-ITGAV, SIRP1a-CD47; Fig. 4E ). The interaction of TGFB1 with its receptor ITGB6/8 likely suppresses beneficial immune responses, as it releases active TGFB1 from its inhibitor latency-associated peptide 38, 39 . Active TGFB1 suppresses cytotoxic T cells, potentially inhibiting clearance of SARS-CoV-2-infected cells, inhibits proliferation of naïve T cells and induces growth arrest of B cells, potentially contributing to COVID-19-associated lymphopenia, and promotes differentiation of peripheral Tregs 40 . Of note, the majority of monocyte ligands function in T cell recruitment, activation, and exhaustion as early as D0 (e.g., CXCL9-CXCR3, CXCL10-CXCR3, IL15-IL2R, CD74-LAG3, CD274-PDCD1; Fig. 4E ). Consistent with this, amongst the subset of severity-associated monocyte ligands that affect receptors on T cells is a coexpressed module of monocyte death-associated cytokines/chemokines (CXCL10, CCL7, CCL8, CCL2; Fig. 4F ). Also notable are two coexpressed modules of receptors on T cells associated with T cell activation and exhaustion (IL18, IL15, and PVR, and CXCL16, CD74 and CD27), the ligands for which are expressed on monocytes (Fig. 4F) . Based on these data, we propose a model of COVID-19-induced immune and cellular responses within the lower airways in which early monocyte activation drives T cell recruitment, activation, and exhaustion, leading to delayed activation of additional monocyte inflammatory pathways and repair and regeneration within lung epithelial cells (Fig. 4G) . This analysis of the plasma proteomes of 384 acutely-ill patients with COVID-19 and non-COVID-19 illnesses provides a comprehensive longitudinal summary of the systemic host response to SARS-CoV-2. We found that COVID-19 patients have dramatically different plasma proteomic profiles than COVID-19-negative controls with respiratory distress (Fig. 1) . We broadly characterize over 600 plasma proteins implicated in the host viral and inflammatory response to SARS-CoV-2. Amongst COVID-19-infected patients, a small subset had inflammatory signatures similar to COVID-19-negative controls but had outcomes similar to those seen with other COVID-19-positive patients. Over 250 proteins were independently associated with COVID-19 severity, with several inflammatory mediators associated with death in ARDS patients, including previously identified markers (IL6 2, 4, 9, 10, [20] [21] [22] , IL8 2, 9, 10, 21, 22 and CXCL10 2, 9, 10, 21 ) and several novel markers (CCL2, CCL7, CCL8, CCL20, AREG, IL1RL1, FLT1 and IL24) (Fig. 2) . Importantly, plasma proteins at D0 are strongly predictive of disease severity. These may identify pathways associated with severity that are amenable to existing or new therapeutics. Furthermore, they can be incorporated into diagnostics that stratify high-risk patients for tailored therapies or earlier intervention. By leveraging scRNAseq datasets from PBMCs of COVID-19 patients and healthy tissues, we deconvoluted the relative contribution of different compartments to the plasma proteome, finding a subset of severityassociated plasma proteins expressed in circulating monocytes and plasmablasts, and a smaller subset in circulating T cells and NK cells. To understand the effect of COVID-19 on host tissues, we leveraged gene expression data from GTEX to derive organ-specific cellular death signatures. By applying the resulting unbiased set of intracellular proteins to severity-associated proteins in plasma proteomes, we demonstrate that severe patients have early signals of heart, lung, and skeletal muscle tissue damage (Fig. 3) . Our derived protein signatures correlate with clinical metrics of tissue-specific cellular damage and, by using scRNAseq data, primarily show gene expression in epithelial cells within the respective tissues, providing support to their validity. Our plasma organ-specific death signatures will have broader utility as a potential liquid biopsy for organ damage and can be used to interpret the plasma proteome in the context of tissue-specific cell death and inflammation. By applying expression profiling of cells from BAL fluid to our intracellular cell death signatures, we demonstrate that the severity-associated proteome is significantly associated with cell-type specific ACE2 gene expression, suggesting that direct infection of lung epithelial cells leads to cell death that is measurable in plasma (Fig. 3) . Of note, we make the assumption that circulating factors reflect the effect of secreted factors in lung tissue, an assumption that requires validation in future studies. By analyzing the interactions of circulating ligands with receptors within cells in BAL fluid, we discover a temporal order of cellular communication in the lung that drives disease severity (Fig. 4) . This starts with early activation of monocytes/macrophages and T cell recruitment into tissues alongside activation and early expression of exhaustion markers. Death of lung epithelial cells in turn activates regenerative and growth factor signaling, and phagocytosis of cells by macrophages (Fig. 4G) , consistent with proposed models of altered differentiation dynamics of nasal epithelial cells upon SARS-CoV-2 infection 37 . By discriminating specific cell types likely dying from direct viral infection from those likely dying from indirect effects of the illness, we provide new details on the pathogenesis of the disease. In conclusion, we studied several thousand circulating proteins within the plasma proteome in a large number of symptomatic COVID-19 patients and acutely-ill non-COVID-19 controls upon hospital arrival and during the first week of hospitalization. We performed adjusted analyses to determine plasma proteins that are independently-associated with COVID-19 disease and illness severity. In patients with ARDS, we identified inflammation-related proteins associated with death, and non-inflammatory, potentially protective proteins that are upregulated in those who survive. By mapping differentially-expressed proteins to published scRNAseq data, we infer cellular origins of relevant circulating proteins and provide an important link between cellular immune responses and tissue damage in severe disease to the clinically-accessible plasma proteome. This work lays the foundation for understanding how the plasma proteome can be leveraged to gain insights into underlying disease pathways and potential therapeutic targets, and to develop diagnostics that can be used to stratify high-risk patients as candidates for tailored therapies and earlier interventions. Patients were enrolled in the Emergency Department (ED) of a large, urban, academic hospital from 3/24/2020 to 4/30/2020 in Boston during the peak of the COVID-19 surge, with an institutional IRB-approved waiver of informed consent. Included were patients 18 years or older with a clinical concern upon ED arrival for COVID-19 and with acute respiratory distress, with at least one of the following: 1) tachypnea (≥22 breaths per minute), 2) oxygen saturation ≤92% on room air, 3) a requirement for supplemental oxygen, or 4) positivepressure ventilation. The day 0 blood sample (N=384) was obtained concurrent with the initial clinical blood draw in the ED, and day 3 (N=217) and day 7 (N=144) samples were obtained for COVID-19-positive patients, if still hospitalized at those times, yielding 735 samples. In addition, blood was collected from some patients at the time of substantial clinical deterioration (44 samples); these event-driven samples were excluded from linear models. Clinical course was followed to 28 days post-enrollment or until hospital discharge, if that occurred after 28 days. Of all 384 enrolled, 78 (20%) tested negative for SARS-CoV-2; among these, for 50 (64%), suspicion for COVID-19 was very low based on careful retrospective chart review by MRF and RPB, an emergency physician and infectious diseases physician, respectively. Among the remaining 28 patients, COVID-19 was a diagnostic possibility yet most had multiple negative PCR tests throughout their hospital course. These 78 subjects were categorized as controls. We dichotomized COVID-19 subjects by illness severity and outcome into severe (A1-A2) and less severe (A3-A5) groups. Of the 42 COVID-19 patients who died, 24 (57%) received mechanical ventilation and 18 (43%) did not. The latter group was significantly older, many with advanced directives to withhold aggressive care. Demographic, past medical history and clinical data were collected and summarized for each outcome group, using medians with interquartile ranges and proportions with 95% confidence intervals, where appropriate. Blood samples were collected in EDTA tubes and processed no more than 3 hours post blood draw in a Biosafety Level 2+ laboratory on site. Whole blood was diluted with room temperature RPMI medium in a 1:2 ratio to facilitate cell separation for other analyses using the SepMate PBMC isolation tubes (STEMCELL) containing 16 mL Ficoll (GE Healthcare). Diluted whole blood was centrifuged at 1200 g for 20 minutes at 20 °C. After centrifugation, plasma (5 mL) was pipetted into 15 mL conical tubes and placed on ice during PBMC separation procedures, centrifuged at 1000 g for 5 min at 4°C, aliquoted into cryovials, and stored at -80°C. Study samples (45 µL) were randomly allocated onto 96-well plates based on disease outcome grouping and were treated with 1% Triton X-100 for virus inactivation at room temperature for 2 hrs. Olink plasma proteomic assays 13 The Olink Proximity Extension Assay (PEA) is a technology developed for high-multiplex analysis of proteins using 1 µL of sample. In PEA, oligonucleotide-labelled monoclonal or polyclonal antibodies (PEA probes) are used to bind target proteins in a pair-wise manner thereby preventing all cross-reactive events. Upon binding, the oligonucleotides come in close proximity and hybridize followed by extension generating a unique sequence used for digital identification of the specific protein assay. With recent developments, PEA enables an increased number of 384 multiplex assays and higher throughput using next-generation sequencing (NGS) as a readout method. PEA probe design is based on addition of Illumina adapter sequences, unique barcodes for protein identification and indexes to distinguish samples in multiplex sequencing. The protocol has also been miniaturized and automated using liquid handlers to further improve robustness and maximize output. The full library (Olink® Explore 1536) consists of 1472 proteins and 48 controls assays divided into four 384plex panels focused on inflammation, oncology, cardiometabolic and neurology proteins. In each of the four 384-plex panels, overlapping assays of IL-6, IL-8 (CXCL8), and TNF are included for quality control (QC) purposes. Library content is based on target selection of low-abundant inflammation proteins, actively secreted proteins, organ-specific proteins leaked into circulation, drug targets (established and from ongoing clinical trials), and proteins detected in blood by mass spectrometry. Selection, classification, and categorization of proteins were based on using various databases (e.g. Gene Ontology), the Blood Atlasthe human secretome (www.proteinatlas.org), a collaboration with the Institute of Systems Biology, Seattle WA, for tissue-specific proteins, www.clinicaltrials.gov for mapping of drug targets, detection of proteins in blood measured by mass spectrometry and finally, various text-mining approaches identifying protein biomarkers described in the literature. The analytical performance of PEA is carefully validated for each protein assay; performance data are available at www.olink.com. Technical criteria include assessing sensitivity, dynamic range, specificity, precision, scalability, endogenous interference, and detectability in healthy and pathological plasma and serum samples. In the immune reaction, 2.8 µL of sample is mixed with PEA probes and incubated overnight at 4 °C. Then, a combined extension and pre-amplification mix is added to the incubated samples at room temperature for PCR. The PCR products are pooled before a second PCR step following addition of individual sample index sequences. All samples are thereafter pooled, followed by bead purification and QC of the generated libraries on a Bioanalyzer. Finally, sequencing is performed on a NovaSeq 6000 system using two S1 flow cells with 2 x 50 base read lengths. Counts of known sequences are thereafter translated into normalized protein expression (NPX) units through a QC and normalization process developed and provided by Olink. The Olink PEA QC process consists of specifically engineered controls to monitor the performance of the main steps of the assays (immunoreaction, extension and amplification/detection) as well as the individual samples. Internal controls are spiked into each sample and represent a control using a non-human assay, an extension control composed of an antibody coupled to a unique DNA-pair always in proximity and, finally, a detection control based on a double stranded DNA amplicon. In addition, each plate run with Olink includes a control strip with sample controls used to estimate precision (intra-and inter-coefficient of variation). A negative control (buffer) run in triplicate is utilized to set background levels and calculate limit of detection (LOD), a plate control (plasma pool) is run in triplicate to adjust levels between plates, and a sample control (reference plasma) is included in duplicate to estimate CV between runs. NPX is Olink's relative protein quantification unit on a log2 scale and values are calculated from the number of matched counts on the NovaSeq run. Data generation of NPX consists of normalization to the extension control (known standard), log2-transformation, and level adjustment using the plate control (plasma sample). The SomaScan Platform for proteomic profiling uses 4979 SOMAmer reagents, single-stranded DNA aptamers, to 4776 unique human protein targets. The modified aptamer binding reagents 32 , SomaScan assay 32,41 , its performance characteristics 29,42 , and specificity 43,44 to human targets have been previously described. The assay used standard controls, including 12 hybridization normalization control sequences to control for variability in the Agilent readout process and 5 human calibrator control pooled replicates and 3 quality control pooled replicates to mitigate batch effects and verify the quality of the assay run using standard acceptance criteria. The SomaScan Assay is run using 96-well plates; 11 wells are allocated for control samples used to control for batch effects and to estimate the accuracy, precision, and buffer background of the assay over time. Five pooled Calibrator replicates, three pooled QC replicates, and three buffer replicates are run on every plate. The readout is performed using Agilent hybridization, scan, and feature extraction technology. Twelve Hybridization Control SOMAmers are added alongside SOMAmers to be measured from the biological samples and controls of each well during the SOMAmer elution step to control for readout variability. The control samples are run repeatedly during assay qualification and robust point estimates are generated and stored as references for each SOMAmer result for the Calibrator and QC samples. The results are used as references throughout the life of the SOMAscan V4 Assay. Plate Calibration is performed by calculating the ratio of the Calibrator Reference RFU value to the plate-specific Calibrator replicate median RFU value for each SOMAmer. The resulting ratio distribution is decomposed into a Plate Scale factor defined by the median of the distribution and a vector of SOMAmer-specific Calibration Scale Factors. Normalization of QC replicates and samples is performed using adaptive normalization by maximum likelihood (ANML) with point and variance estimates from a normal U.S. population. Post calibration accuracy is estimated using the ratio of the QC reference RFU value to the plate-specific QC replicate median RFU value for each SOMAmer. The resulting QC ratio distribution provides a robust estimate of accuracy for each SOMAmer on every plate. Plate-specific Acceptance Criteria: Plate Scale Factor between 0.4-2.5 and 85% of QC ratios between 0.8 and 1.2 must be met prior to release. All statistical analyses for the clinical and proteomics data in this cohort was performed using R version 4.0.2. All plots were generated using the ggplot2 package in R with the exception that the correlation plots were generated using the corrplot() function in R. Pairwise Pearson correlations were calculated for all proteins, and rows and columns of correlation plots were ordered based on hierarchical clustering. All heatmaps were generated using the heatmap3 45 package and NPX values for each protein centered to have a mean of 0 and scaled to have a standard deviation of 1 within each protein. Scaled data greater than either 4 or 5 standard deviations from the mean were truncated at +/-4 or 5. Rows and columns were ordered based on hierarchical clustering. Principal components analysis (PCA) was performed using all proteins and all samples using the prcomp() function in R. Unsupervised clustering by UMAP was performed using all proteins, and either all samples or just day 0 samples, using the umap() function in R, and UMAP coordinates were plotted using the ggplot2 package. Unsupervised clustering by tSNE was by first performing dimensionality reduction by PCA and then taking the top principal components for a tSNE embedding using the Rtsne package and the argument pca=TRUE. k-nearest neighbor (KNN) graphs and Louvain community detection was performed using custom code and the FNN package provided in R. Linear regression models were fit independently to each protein using the lm package in R with protein values (NPX for Olink data) as the dependent variable. The models included a term for COVID-19 status and covariates for age, sex, ethnicity, heart disease, diabetes, hypertension, hyperlipidemia, pulmonary disease, kidney disease, immuno-compromised status to control for any potential confounding. P-values were adjusted to control the false discovery rate (FDR) at 5% using the Benjamini-Hochberg method implemented in the emmeans package in R. Linear mixed effects models (LMMs) were fit independently to each protein using the lme4 46 package in R with protein values (NPX for Olink data) as the dependent variable. The model for severity included a main effect of time, a main effect of severity, the interaction between these two terms, and a random effect of patient ID to account for the correlation between samples coming from the same patient. Covariates for age, sex, ethnicity, heart disease, diabetes, hypertension, hyperlipidemia, pulmonary disease, kidney disease, and immuno-compromised status were included in the model to control for any potential confounding. Significance of the three model terms was determined with an F-test using Satterthwaite degrees of freedom and type III sum of squares implemented with the lmerTest 47 package in R. P-values for the three model terms of interest were adjusted to control the FDR at 5% using the Benjamini-Hochberg method. Group differences were calculated for each protein passing the FDR threshold with p-values adjusted using the Tukey method implemented by the emmeans package in R. Group differences with Tukey adjusted p-values less than 0.05 were considered statistically significant. Note, all other models were run similarly with time in addition to either Acuity max , age, or both age and severity as main effects instead of severity. For SomaLogic data, LMMs for severity and time as main effects were run as was done for Olink. Overall, significant proteins were found to be partially overlapping with those found for Olink; for example, at D0, of the 1085 overlapping assays between the two platforms, 779 proteins were significant for severity or interaction term in Olink data, and 669 in the SomaLogic data, with 460 proteins overlapping between the two sets. The non-overlapping assays in part due to a narrower dynamic range for some of the SomaLogic assays. Model residual values were extracted from LMMs (as described above) independently fit to every protein using NPX as the dependent variable, age, sex, ethnicity, heart disease, diabetes, hypertension, hyperlipidemia, pulmonary disease, kidney disease, and immuno-compromised status as covariates and a random effect of patient ID to account for the correlation between samples taken from the same patient. These residuals represent the remaining unexplained variance in the protein expression after accounting for the effects of the included covariates. For the Olink assay, the likelihood of observing 1131 statistically significant proteins for the Acuity max model term and 963 statistically significant proteins for the time and Acuity max interaction term from the linear mixed models was evaluated using permutation testing. Acuity max group was randomly permuted 100 times among patients and for each permutation the full LMM procedure was followed. None of the permutations produced as many statistically significant results as were observed when using the true Acuity max groupings. For analysis of functional pathways, two different strategies were employed: (i) gene set enrichment analysis 48 using the ClusterProfiler package in R using the C7 immunologic signature gene set from the molecular signatures database v7.2 (https://www.gsea-msigdb.org/gsea/msigdb); and (ii) Ingenuity Pathway Analysis (Qiagen) on our gene lists using default parameters from the vendor. Pathways were visualized in dot plots and bar plots using the ggplot2 package in R. To identify plasma proteins that were differentially expressed between Louvain clusters, we created a linear model (as described above) with an identifier variable for Louvain group as a main effect and clinical variables (as described above) as covariates; that is, for proteins most significantly expressed in L1, our identifier variable was a 1 for L1 and 0 for all other groups. The top 25 differentially-expressed proteins were then visualized. Predictive performance of severity within 28 days was performed using all proteins and model covariates and was estimated using elastic net logistic regression implemented by the glmnet 49 package in R and 100 repeats of 5-fold cross validation. Model tuning was performed using the caret package in R. Variable scaling, model tuning, and feature selection was performed independently for each held-out fold such that the predictive model was never exposed to the held-out data. Measures of predictive performance are reported as medians and 95% confidence intervals calculated from the 100 repeats of the cross validation. Features were ranked by how frequently they were chosen to be included in the model. Generalized linear models with lasso regularization were trained (using the R caret package) on COVID-19positive patient proteome samples (consisting of 1472 Olink protein features) from each selected day (0, 3, and 7) to predict patient age (≤ or > 65 years) or neutralization levels (≤ or > 75%). For percent neutralization predictions, protein levels at day 0 were used to predict binned neutralization categories at day 3. Repeated 5-fold cross validation (with a hyperparameter scan from 0.0001 to 1 to select the lambda constant yielding the greatest prediction accuracy) was replicated 100 times to obtain a confidence interval for the area under the ROC curve (where ROC curves were generated using each patient's estimated probability while serving as the held-out fold). The average feature weights of the final models from each of the 100 rounds of 5-fold cross validation were used to identify proteins of importance. Orthogonally, 10-fold cross validation was used to train and validate a random forest model (with default ntree=500 and mtry=38) to predict age (≤ or > 65 years) or neutralization quartiles (0-25, 25-50, 50-75, 75-100%) and important proteins were identified based on mean decrease in Gini. To identify protein features that were independent from or overlapping with severity markers, the union of the top 50 important features from the lasso and random forest models were intersected with significantly variable proteins between severity groups on day 0 (from the LMM described above). SARS-CoV-2 S was amplified by PCR (Q5 High-Fidelity 2X Master Mix, New England Biolabs) from pUC57-nCoV-S (gift of Jonathan Abraham), in which the C-terminal 27 amino acids of SARS-CoV-2 S are replaced by the NRVRQGYS sequence of HIV-1, a strategy previously described for retroviruses pseudotyped with SARS-CoV S 50 . The truncated SARS-CoV-2 S fused to gp41 was cloned into pCMV by Gibson assembly to obtain pCMV-SARS2ΔC-gp41. psPAX2 and pCMV-VSV-G were previously described 51 . pTRIP-SFFV-EGFP-NLS was previously described 52 (Addgene plasmid #86677). cDNA for human TMPRSS2 and the hygromycin resistance gene were generated by synthesis (Integrated DNA Technologies). pTRIP-SFFV-Hygro-2A-TMPRSS2 was generated by Gibson assembly. 293T cells were cultured in DMEM, 10% FBS (ThermoFisher Scientific), and PenStrep (ThermoFisher Scientific). 293T ACE2 cells (gift of Michael Farzan) were transduced with pTRIP-SFFV-Hygro-TMPRSS2 using TransIT®-293 Transfection Reagent (Mirus Bio, MIR 2700) to obtain 293T ACE2/TMPRSS2 cells, which were selected with 320 µg/ml of hygromycin (Invivogen) and used as a target in pseudotyped SARS-CoV-2 S lentivirus neutralization assays. The protocol for lentiviral production was previously described 51 . Briefly, 293T cells were seeded at 0.8 x 10 6 cells per well in a 6-well plate and were transfected the same day with a mix of DNA containing 1 µg psPAX, 1.6 µg pTRIP-SFFV-EGFP-NLS, and 0.4 µg pCMV-SARS2ΔC-gp41 using TransIT®-293 Transfection Reagent. After overnight incubation, the medium was changed. SARS-CoV-2 S pseudotyped lentiviral particles were collected 30-34 hrs post medium exchange and filtered using a 0.45 µm syringe filter. To transduce 293T ACE2 cells, the same protocol was followed, with a mix containing 1 µg psPAX, 1.6 µg pTRIP-SFFV-Hygro-2A-TMPRSS2, and 0.4 µg pCMV-VSV-G. The day before the experiment, 293T ACE2/TMPRSS2 cells were seeded at 5 x 10 3 cells in 100 µl per well in 96-well plates. On the day of lentiviral harvest, 100 µl SARS-CoV-2 S pseudotyped lentivirus was incubated with 50 µl of plasma diluted in medium to a final concentration of 1:100. Medium was then removed from 293T ACE2/TMPRSS2 cells and replaced with 150 µl of the mix of plasma and pseudotyped lentivirus. Wells in the outermost rows of the 96-well plate were excluded from the assay. After overnight incubation, medium was changed to 100 µl of fresh medium. Cells were harvested 40-44 hrs post infection with TrypLE (Thermo Fisher), washed in medium, and fixed in FACS buffer containing 1% PFA (Electron Microscopy Sciences). Percentage GFP was quantified on a Cytoflex LX (Beckman Coulter), and data was analyzed with FlowJo. We analyzed 4 publicly available scRNAseq PBMC datasets from COVID-19 patients, which were obtained To generate lung cell-type specific signatures, we collected and aggregated scRNAseq studies, normalized each dataset, harmonized the published cell type annotations, and trained a multiclass logistic regression model. Only studies with scRNAseq data from primary tissue (including healthy, fibrotic, and COVID-19 donors), sequenced using the 10X Genomics platform, and published annotations were included. Two additional studies (chosen to maximize the number of cell types in the test set) were held out for cross validation to test cell type predictions and tune hyperparameters. The training datasets were Adams et al, Normalization: Single cell/nuclei RNA-seq datasets from individual studies were aggregated and normalized using Scanpy 63 . Each study was subjected to identical pre-processing steps. First, UMI count values were winsorized, those above the 99th percentile of non-zero counts were reduced to the value of the 99th percentile (13 counts). Winsorized count data were normalized, so that UMI counts per cell/nucleus summed to 10,000, and then were logged, resulting in log(1+10,000*UMIs / total UMIs) for each cell/nuclei ("logtp10k"). Then the aggregated expression data were scaled using the scanpy `scale` function with zero_center=False. To prepare cell type labels, we mapped each annotation to a common reference list before training. Cells labeled with cell types with ambiguous mappings (e.g. "T cell" or "myeloid") were excluded from training. Signature extraction: Cell type signatures were learned using an L2 penalized logistic regression model trained to predict the cell type from a single cell gene expression profile. The model was trained using SciKitLearn's LogisticRegression function with the default parameters with the exception of C=.1, max_iter=30, and multi_class='ovr'. During fitting, individual cells were weighted to balance with respect to both cell type and study. Model coefficients learned were used as cell type signatures. All scRNAseq gene expression data was analyzed in R version 4.0.2 using custom code to look at average expression of genes of interest in each cell type. For visualization, gene expression was normalized across cell types (rows) with Z-scores and visualized in heatmaps using the heatmap3 function in R with hierarchical clustering of both cell types and genes. Where cell types were annotated on heatmaps, this was done by identifying cell types with the highest relative expression by Z-scores. The cell-type-specific intracellular gene list was defined as the top 20 genes with the highest relative expression for that cell type. Organ specific protein signatures were defined using RNA sequencing data from the Genotype-Tissue Expression (GTEx) Portal (https://www.gtexportal.org/home/). The median transcripts per million (TPM) of 56,200 genes across 54 non-diseased tissue sites were obtained. For each tissue site, the intersection of the top 500 highest TPM genes and the top 500 most variable genes (based on coefficient of variation across tissue types) was identified (Table S14). Proteins that were also measured by SomaScan were extracted, validated for high tissue specific expression, and consolidated across related tissues for each organ of interest. Organ signatures were split based on localization (intracellular versus membrane/secreted) using UniProt and literature annotations. The values for each protein across all COVID-19-positive patients were scaled to Z scores, and the mean Z score of all proteins in an organ set was used as an overall signature score for a given patient. The metadata cluster identities were previously assigned based on the published annotations. Analysis of specific ligands and receptors was performed from a curated list of known ligand-receptor pairs, and cell types were assigned to particular ligands and receptors by identifying cell types with the highest relative expression by Z-scores. Data for the Olink proteomics assay (1352 proteins screened in 384 patients) is publicly available at https://www.olink.com/mgh-covid-study/. All other data and code will be made available at the time of publication. Table S1 . Clinical metadata and associations with outcome for all patients in this cohort. Table S2 . List of proteins assayed using the Olink proteomics platform. We also thank the Departments of Emergency Medicine and Medicine for their financial support in maintaining needed staffing levels during enrollment, when many research funding sources were being suspended. We DDX58 TRIM21 IL18R1 TNFSF14 CCL7 KRT18 KRT19 PLA2G2A IL15 CLEC11A CD274 CD70 CSF1 CD14 C1QA CD48 LAG3 SIGLEC1 IFNγR2 C2 CLEC4G IFNγ IFNλ1 CXCL10 CCL8 CXCL11 GZMB GZMH CD1C ITGAV ITGB1 TMPRSS15 SERPINA9 IL7R CD6 PDGFRB CD58 CCL16 CCL24 CLEC4A ICOSLG CD207 TNFRSF10C CCL14 KLK13 CD93 TGFBR3 TNFRSF21 IL10RB CD46 TNFRSF4 TNFRSF9 TYMP GRN SIGLEC1 TPP1 FBP1 LGALS9 IL1RN HSPA1A SIGLEC5 NADK WARS CTSH LAP3 RRM2 GBP2 IFNγ LAG3 IL18R1 PTX3 CLEC11A ALDH1A1 TNFSF14 DDX58 TRIM21 MAD1L1 NID1 FURIN CTSO GRPEL1 BRK1 CXCL10 MATN3 CCL8 C1QA TCN2 FOLR2 LGMN NPM1 ST6GAL1 SAMD9L SHMT1 CASC4 PSME1 BST2 PSME2 PRDX1 RBCs (12) RBCs (14) Platlets (17) Eosinophils (24) Class-switched B cells (9) IgA plasmablasts (29) IgA plasmablasts ( SEMA4D CDH2 CD274V ANGPT2 GDF15 PCDH1 IGFBP2 RETN CLEC4D PDGFRA TNFSF13 IL18BP IFNγR1 TNFRSF12A TNFRSF11A TNFRSF14 CX3CL1 LAYN CCL17 TNFSF12 FKBP5 LBR FETUB IGFBP3 APOM FASLG OMG IL18R1 TPP1 CEACAM1 ACE2 SUSD2 DKK1 CD177 OSM RNASE3 MZB1 IL15 CTSB CCL2 CXCL8 CCL7 ST3GAL1 RRM2 CXCL9 TNFRSF10B TNFRSF6B IL6 IL1RL1 TXNRD1 IL22RA1 ANXA8 PTK6 LEMD1 TMPRSS11A KMT5C DNAJB2 TNFRSF10D MATK GZMH BATF SIRPG ICAM3 IL21R TMPO PSIP1 YEATS4 CHEK1 CCNB2 CCNA2 AURKB BIRC5 SUB1 NPM1 HNRNPA1 RPL12 RPS3 RPS7 LDHB REXO2 CBX5 SSRP1 MYL6B LDHA HMOX2 SUMO2 CELF2 PSME1 HPRT1 BLMH HIKESHI CUTC VRK1 SMC3 TPI1 DCXR PGLS GDI2 ISCU MRPL34 APEX1 RBBP4 ITGB6 OSMR MET LRP6 EGFR KIT BMPR1B PTPRZ1 ITGB8 IL20RB FGFR2 ACKR4 IL20RA FZD6 PLXNB2 ST14 SDC4 LIFR TNFRSF21 PTPRS DPP4 ITGB1 SORL1 TGFBR2 TRAF2 KREMEN1 NRP2 ITGAV ACVR1B ACVR1 IL17RE PLXNA3 FZD8 PLXNA1 INSR LGR4 IL22RA1 KDR NOTCH3 RET IL6ST BMPR1A LRP5 ZNRF3 ACVR2B ACVR2A day 0 and 3 KIT MET LRP6 EGFR CCR6 IL7R SELPLG IL18RAP CD226 IL18R1 CD96 TIGIT CCR1 HAVCR2 ITGA5 FLT1 CXCR2 CXCR1 TNFSF14 NRP1 NOTCH2 NRP2 PLXNA3 PLXNA1 KREMEN1 ITGB1 TGFBR2 IL2RG PVRIG CX3CR1 NOTCH1 KREMEN2 ALK CCR3 NOTCH4 PTPRS RET IL6ST PTPRZ1 IL20RA PLXNB2 IL20RB KDR NOTCH3 LIFR ST14 LRP5 LTBR PVR IL18 NECTIN2 HGF CCL15 IL7 DLL1 VSIR IL19 CCL20 PGF CTF1 ARTN CXCL8 PLAU VEGFA CEACAM1 GDF15 HSPG2 TNC LIF DKK1 GAS6 SEMA4C KITLG CCL2 SPP1 TIMP1 SIRPRA CXCL10 TGFB1 CXCL11 CXCL9 NECTIN2 CCL3 TNFSF13B NAMPT CD274 CXCL8 CXCL16 LRPAP1 TNFSF13 IL18 IL15 IL6 TNFRSF14 CCL20 CXCL1 CCL4 TNF MDK CD74 CD63 CCR1 ITGB6 PTPRZ1 ITGB8 INSR TNFRSF21 TNFRSF13B CCR6 SORT1 TNFRSF1A CD47 IL6R IL15RA ITGAV CD4 TNFRSF17 TGFBR2 ACKR3 TGFBR1 ITGA9 ITGB3 CCR3 ALK ACVR1 SORL1 CXCR2 CXCR1 TNFRSF1B CCR5 IL2RG CCR2 PVRIG IL6ST BTLA PDCD1 ITGB1 TRAF2 IL18RAP S1PR1 IL18R1 IL2RA TIGIT IL2RB CXCR6 LAG3 CXCR3 ITGA4 CSF1 LGALS9 TNFSF12 HAVCR2 CSF1R TNFRSF12A D CCR6 CCR7 ITGA1 CD244 IL18RAP CD226 IL2RB CXCR3 ITGA4 CXCR6 CD96 LAG3 IL6ST CD4 SELPLG CXCR4 TNFSF14 TNFRSF14 CCR5 IL2RG CCR2 PVRIG BTLA CD70 PDCD1 IL18R1 DPP4 IL7R S1PR1 IL2RA TIGIT CCL8 CXCL11 CCL19 IL18 CD48 SEMA7A IL15 PVR CXCL10 CCL7 CCL2 IL6 CTF1 IL7 VSIR CD274 OSM TNFSF14 LIF CCL20 CXCL12 CCL4 CCL3 CXCL9 CXCL16 SPP1 CD74 CD27 LTBR TNFRSF14 NECTIN2 NECTIN2 TNFRSF14 LTBR CD27 CD74 SPP1 CXCL16 CXCL9 CCL3 CCL4 CXCL12 CCL20 LIF TNFSF14 OSM CD274 VSIR IL7 CTF1 IL6 CCL2 CCL7 CXCL10 PVR IL15 SEMA7A CD48 IL18 CCL19 CXCL11 SPP1 GDF15 TGFA TNC CXCL13 CXCL12 PLAU SEMA7A SPINT1 SEMA4C COL4A1 CCL19 HSPG2 PGF DLL1 SEMA3F TNF IL17C IL19 FGF21 IL24 RSPO1 MDK RSPO3 CCL21 SFRP1 PTN HGF BMP6 ARTN IL6 LIF OSM NAMPT INHBC VEGFA DKK1 TGFB1 CD40LG EGF LRPAP1 CTF1 VEGFD KITLG MSTN SPP1 GDF15 TGFA TNC CXCL13 CXCL12 PLAU SEMA7A SPINT1 SEMA4C COL4A1 CCL19 HSPG2 PGF DLL1 SEMA3F TNF IL17C IL19 FGF21 IL24 RSPO1 MDK RSPO3 CCL21 SFRP1 PTN HGF BMP6 ARTN IL6 LIF OSM NAMPT INHBC VEGFA DKK1 TGFB1 CD40LG EGF LRPAP1 CTF1 VEGFD KITLG E RNASET2, CLEC1A, VCAM1, PDFGRA, CD97, LTBP2, CD163, CCL27, LILRB1, IL18BP, TNFSF13B, ICAM2, IL19, TIE1, SDC1, IL8, IL2RA, CDH2, CTSB, DKK3, TNF, CD59, IL1RL, IL17A, TNFSF13, CD4, IL10, IL4R, SIGLEC10, IL12RB1, IL17C, CXCL9, IL1B, CCL1, IL20, CD48, CSF1, TNFRSF11B, CCL19 ,PLA2G10, TNFRSF10A, TNFRSF6B, CD8A, HAVCR2 ,CD300C, TNFRSF8, CD74, CD274, FLT3 SLAM6, GNLY, LILRA2, LILRB1, LILRB2, IL17RB, IL18, LILRA5, CD274, VISG4, TNF, IL12RB1, TNFSF13, HLA-E, CD38, CD30E, LILRB4, FCRL2, FCRLB, TNFRSF13B, MZB1, IL5RA, SLAMF7, CCL2, IL1RN, IL6, AGER, AGR2, KRT19, KRT18, LGALS9, JUN, F9, ITIH3, CLEC4G, IL6R, IFNLR1, TNFRSF8, CD70, RRM2, BRK1, CCL7, NADK, WARS, DCTPP1, TNFSF14, VWF, IL15, SLC39A14, FALNT2, PCSK9, PLA2G2A IL1RN SIGLEC1 TCN2 PTX3 ALDH1A1 CES1 FKBP5 CTSO SIGLEC5 CXCL10 FOLR2 NID1 CLEC11A SORD FURIN HSPA1A TPP1 NADK LAP3 BRK1 BST2 PSME2 PRDX1 GBP2 PSME1 FBP1 LGALS9 Severity IL2 FCRL5 IL11 WFIKKN1 APP NID2 F9 TNFRSF8 BPIFB1 KITLG COMP NTRK2 C R TAC1 ITGA11 CBLIF PLA2G10 DKK3 KLK10 LGALS7B LEFTY2 CD300LG TFF1 TFF2 CCL25 CD34 ICOSLG PEAR1 PTH1R K R T5 CES2 CCL8 IFNL1 HSD11B1 TNFSF10 CD1C ENPP5 EGFR ERBB4 PTEN CRHR1 Non-severe Age Group <65 65+ Timepoint D0 D3 D7 Severity Age group Timepoint CD99_OID21110 EFNA4_OID20935 CST3_OID20400 BSG_OID20626 CD300C_OID21010 ESAM_OID20270 BCL2L11_OID20513 FAS_OID20316 E DA2R_OID21451 CD27_OID21527 EPHA2_OID21342 CGREF1_OID20152 WISP2_OID21068 EGFL7_OID21252 IL15RA_OID20498 NUCB2_OID21448 IL18BP_OID20348 GPR37_OID20095 PHOSPHO1_OID20922 IL19_OID20158 PILRA_OID21129 APOH_OID21072 NEFL_OID20871 SIGLEC10_OID20537 SPON2_OID20221 CLSTN2_OID20664 MMP10_OID20687 ANGPT2_OID21463 IL6ST_OID20147 ICAM2_OID20248 CRIM1_OID20701 PIK3IP1_OID21094 NBL1_OID21486 CLMP_OID21419 SORCS2_OID21262 PTPRN2_OID20912 CLEC1A_OID20099 TFF3_OID20371 CST5_OID20995 TNFRSF21_OID21052 EFEMP1_OID20414 FGF5_OID20490 WNT9A_OID20460 DKK3_OID20264 LPL_OID20188 CA12_OID21344 NPPB_OID20049 ESM1_OID20758 MICB_MICA_OID20593 LILRB2_OID20301 AR TN_OID20446 MDK_OID21489 HGF_OID20656 ENPP2_OID20288 CD163_OID20360 TIE1_OID20303 SERPINA9_OID21284 BIN2_OID21067 STXBP3_OID21240 TACC3_OID21285 MAP3K5_OID21253 TIA1_OID20068 ICA1_OID20484 ITGB5_OID21522 PTPN1_OID20908 SCAMP3_OID21332 CLEC1B_OID21061 IPCEF1_OID20977 MPI_OID21288 PRDX3_OID20483 PODXL_OID21358 FOSB_OID20791 PCOLCE_OID20384 GGH_OID20416 LRRN1_OID20438 QPCT_OID20320 FBP1_OID20227 NCLN_OID20448 XPNPEP2_OID21508 FMNL1_OID20884 MMP9_OID21103 MARCO_OID20210 PLA2G7_OID21105 FOXO3_OID21271 GRK5_OID20066 TINAGL1_OID20180 SCGN_OID20457 CXCL8_OID21430 CAPG_OID21431 AMBN_OID20437 COL4A1_OID20208 FABP1_OID20778 IGFBP3_OID20398 CSF3_OID20491 BAG3_OID20972 CXCL8_OID20631 PPM1A_OID21184 ALDH3A1_OID20512 PAMR1_OID21153 TYRO3_OID20161 PEBP1_OID21087 DCTN2_OID21334 CDKN2D_OID21295 MPIG6B_OID20779 TIE1_OID20303 TMSB10_OID21118 LAIR2_OID20965 IFNG_OID20495 ACE2_OID20105 SF3B4_OID21278 LBR_OID21034 AREG_OID21357 GP2_OID20090 ENPP5_OID20736 CLEC5A_OID20165 ACTA2_OID20079 ANGPT2_OID21463 FLT1_OID21301 PLIN3_OID20143 NPM1_OID20961 NMNAT1_OID20913 age.decile[60,70) PPP1R9B_OID20643 SFTPA2_OID21218 CXCL8_OID20997 GUSB_OID20296 CXCL8_OID20153 ANG_OID20403 PCSK9_OID20235 SELPLG_OID20560 TNNI3_OID20050 DFFA_OID20620 ITGA6_OID20528 PROK1_OID20543 BANK1_OID20594 INPP1_OID21345 GBP2_OID20489 ANGPTL7_OID21412 IL6R_OID20385 ENO1_OID21037 CD1C_OID21483 SEMA4C_OID21329 FCRL1_OID20172 AMN_OID20492 NPPB_OID20049 WFIKKN1_OID20939 SERPINB8_OID20630 ST3GAL1_OID21322 RBP2_OID21365 age.decile[50,60) UMOD_OID20237 SLAMF6_OID21254 WISP1_OID21444 KLRD1_OID20632 LSP1_OID20530 Immuno.comprimised1 CCL7_OID20523 HPGDS_OID21266 CTSF_OID21500 PTS_OID20847 SDC1_OID20169 TACSTD2_OID21447 ADM_OID21467 RETN_OID20327 POLR2F_OID21283 BLMH_OID20336 FABP2_OID20200 OSCAR_OID20776 NADK_OID20178 CCL22_OID20765 NCAN_OID21055 SCGB3A2_OID20723 CEACAM5_OID21171 CR2_OID20393 NTproBNP_OID20125 IL15_OID20562 CD34_OID21025 PRDX1_OID20962 CTSV_OID21405 IKZF2_OID21213 PXN_OID20822 MATN3_OID20979 CXCL10_OID20697 APOM_OID20374 CRHBP_OID20747 CLUL1_OID20198 CDHR5_OID20193 TNFSF12_OID20624 BCAN_OID20998 ENTPD6_OID20100 EPO_OID20522 MUC13_OID20866 OSM_OID20574 S100A12_OID21374 CD200R1_OID20595 TCL1B_OID20058 CCL17_OID20745 KRT18_OID21296 LTA_OID20586 MYOC_OID21121 OMG_OID21352 CLEC4C_OID20547 ANGPTL1_OID20211 CLTA_OID20118 APLP1_OID20164 PLA2G2A_OID20274 PROC_OID20402 F3_OID21440 S100P_OID20103 FETUB_OID20404 LTBP2_OID20254 IFNL1_OID20795 F7_OID20372 SETMAR_OID20948 DNER_OID20712 SEMA4D_OID21020 IGFBP1_OID20246 ADGRG1_OID21294 FASLG_OID20665 KDR_OID21497 MMP8_OID21019 AGER_OID20756 EZR_OID21017 AGR2_OID20896 MAPK9_OID20557 NDRG1_OID20792 TNFRSF11B_OID20735 EPS8L2_OID21397 IL1RN_OID20700 DDAH1_OID21299 PTX3_OID20570 CHI3L1_OID20399 TRIAP1_OID21403 IL6_OID21276 IL6_OID20563 IL1RL1_OID20250 IL6_OID20911 IL6_OID20101 SDC1 TXNDC5 S100A4 FGR LGALS1 VCAN CD300E TYMP CTSB BLVRB LGALS3 VNN2 IL8 NAMPT CD74 CTSL TIMP1 MSR1 VSIG4 LGALS9 RBP5 PRELP NOS1 TNC SCLY RBKS SPINK1 SNCG PCSK9 IGFBP2 ACTA2 CCL2 GDF15 ALDH3A1 CCDC80 AK1 DAG1 SETMAR ACY1 THBS2 WFDC2 CCL20 ANGPT2 ANGPTL4 LTBP2 EFNA1 LGALS4 TNNI3 SULT2A1 ANGPTL1 IL6 LHPP ACE2 FLT1 SORD LAYN TNFRSF11A CXCL9 NPDC1 SCGB3A2 VWA1 IL5RA SPP1 IL1RL1 LXN FMNL1 OSM CD274 TGFA FKBP5 IL4R ALDH1A1 ASGR1 HNMT TNFRSF10B IL15 PVR HGF FURIN TGM2 ACVRL1 MATN3 CXCL10 EPHA2 IL18R1 NDRG1 EPS8L2 TNFRSF11B BRK1 SRP14 PHOSPHO1 VWF CA2 NUCB2 CD59 EZR ST6GAL1 SLC39A14 ADA B4GALT1 GALNT2 SAMD9L LBR CXCL13 BLMH CASC4 DCXR NUDC THOP1 SHMT1 NDUFS6 MCFD2 RBCs (12) RBCs (14) Platlets (17) Eosinophils (24) Class-switched B cells (9) IgA plasmablasts (29) IgA plasmablasts (21) IgA plasmablasts (23) IgG plasmablasts (18) IgG plasmablasts (16) NK cells (0) NK cells (11) Memory CD8 T cells (1) Memory CD8 T cells (15) pDCs (26) CD16 monocytes (8) CD14 monocytes (3) Activated granulocyte (27) Neutrophil (25) CD16 monocyte (10) Dendritic cell (20) CD14 monocyte (7) SDC1 CRELD2 TXNDC5 S100A4 FGR LGALS1 VCAN CTSB CD300E TYMP VNN2 CLEC4D FCAR ADM IL8 NAMPT CD74 WARS LAP3 LILRB4 SCARB2 BLVRB LGALS3 ASGR1 KYNU FBP1 LGALS9 LTBR TPP1 PLAUR NADK TGM2 CXCL10 VSIG4 TIMP1 CTSL MSR1 SPON2 CST7 BTN3A2 IL4R FKBP5 ST3GAL1 NPDC1 HNMT ACVRL1 FURIN FMNL1 TNFRSF10B PVR HGF TNFRSF1A ALDH1A1 ANGPTL7 RSPO3 TNFRSF12A IGSF3 EDA2R TIMP4 GPR37 AGRP FABP4 SNCG CCL20 CCL7 DKK1 MYOC LTBP2 LGALS4 RBP5 PRELP ANGPTL1 WISP1 PCSK9 C1QTNF1 PLAT FABP2 CDHR2 MB CHGB WFDC2 AK1 ANGPT2 IGFBP2 ENAH MUC13 FABP1 DCN DAG1 ACY1 ACTA2 IL6 FLT1 CCL2 GDF15 CXCL9 IL15 RBKS TNFRSF11A ACE2 TGFA PLA2G2A TNC VWA1 SPP1 IL1RL1 CRIP2 TNFRSF10A THBS2 DDAH1 SETMAR CD274 OSM SCGB3A2 CXCL13 DCXR LHPP LAYN BRK1 FSTL3 MATN3 ALDH3A1 CCDC80 IL5RA TNNI3 EFNA1 TINAGL1 ANGPTL4 MMP3 CCL23 LXN SORD IL18R1 NDRG1 SRP14 EPHA2 TNFRSF11B EPS8L2 B4GALT1 ADA VWF CA2 IL1R2 PHOSPHO1 SULT2A1 SCLY NOS1 STC1 SPINK1 PTX3 CLEC5A OLR1 TFF3 CHI3L1 RETN RNASE3 LCN2 TACSTD2 CEACAM8 PRTN3 CKAP4 RRM2 NUCB2 CD59 EZR ST6GAL1 SLC39A14 PRDX1 LBR SAMD9L GALNT2 DNPH1 NUDC SHMT1 BLMH THOP1 CASC4 MCFD2 PDC CDC2 NC_MONO C_MONO C_MONO_IFN SLC39A14 NPDC1 MCFD2 LILRB4 LXN CRELD2 THOP1 IL18R1 ANGPT2 SRP14 ANGPTL1 TXNDC5 MZB1 EPS8L2 TNFRSF11B EPHA2 NUCB2 WFDC2 B4GALT1 CHGB NDRG1 SCARB2 NADK GALNT2 WISP1 LTBP2 DAG1 GDF15 ADGRG1 CHI3L1 SCGB3A2 MUC13 ST6GAL1 AK1 SPON2 IDI2 ADA TINAGL1 PLAT CD74 NUDC BRK1 DCXR CD59 MB EDA2R DNPH1 NDUFS6 SULT2A1 VWA1 LAYN IL1RL1 EZR CA2 ALDH3A1 SPINK1 OSM OLR1 CRIP2 VSIG4 LHPP TACSTD2 EFNA1 SETMAR TNFRSF11A CCDC80 IL5RA BLMH SORD CST7 TGM2 IL1R2 ACY1 CXCL9 TNFRSF12A SDC1 ANGPTL7 LAP3 SPP1 ACTA2 TPP1 FURIN RRM2 IGFBP2 RNASE3 TIMP4 LCN2 RETN PRTN3 CCL2 FKBP5 HSPB6 ADM FLT1 TNNI3 SAMD9L CTSB LBR PRELP CASC4 ENAH LGALS4 IL6 RBP5 PHOSPHO1 FSTL3 VNN2 VWF CKAP4 VCAN AGRP SNCG CLEC5A CLEC4D CCL7 IL4R ACVRL1 TNFRSF10A BLVRB LTBR TNFRSF1A ASGR1 PTX3 TNC TGFA FCAR ALDH1A1 ANGPTL4 DKK1 CCL20 CDHR2 HNMT RBKS TNFRSF10B PLAUR LGALS3 FGR S100A4 FMNL1 FBP1 CCL23 SHMT1 LGALS9 TYMP TIMP1 LGALS1 CD274 CXCL10 DDAH1 BTN3A2 IGSF3 HGF IL15 ST3GAL1 CD300E NAMPT PVR CTSL MSR1 WARS PRDX1 SCLY A B ACVRL1 CCDC80 CD79B CD93 CLSTN2 COL6A3 COLEC12 CST3 CTSF EPHA2 EPHB4 FAM3C FST FUT3_FUT5 GAS6 GFRA1 HAVCR1 HAVCR2 QPCT REG1A REG1B REG3A SPON2 SPP1 TFF2 TNFRSF10B TNFRSF11A TNFRSF12A TNFRSF12B TNFRSF14 TNFRSF19 VCAM1 VSIG4 WFDC2 WISP1 APOH ARSA BSG CA3 CCL23 CCL7 CCL8 CDHR2 CLPS CPA1 CPA2 CPB1 CST6 CTRB1 CXCL10 FAM3B FMNL1 IL6 MEPE PLA2G1B PRL PRSS2 RARRES2 SLC16A1 SLC39A14 ADAMTS15 AGRP ANGPT2 ANGPTL3 ANGPTL4 ATOX1 B4GALT1 CALB1 CALCA CANT1 CCL15 CCL2 CCL3 CD14 CD300C CD300LF CD300LG CD59 CD99 CDCP1 CDH1 CDH3 CEACAM21 CEACAM8 HDGF HMOX2 HSPG2 HTRA2 HYOU1 IFNGR2 IGF1R IGFBPL1 IL1RL2 INPP1 LBP MIF MZB1 NADK PGLYRP1 PLA2G2A PON3 PTX3 PXN RASSF2 RCOR1 RELT REN CFC1 CLEC4D CRLF1 CSF1 CSTB DBI DCTPP1 DKK1 EFNA1 EFNA4 EGLN1 ENAH ENPP5 F2R FGF23 FKBP4 FLT1 FURIN GALNT2 GBP2 GNLY GRN RNASE3 RTN4R SDC1 SEMA4C SERPINE1 SF3B4 SIGLEC10 SLC39A14 SPINK1 SPINK6 SPINT2 STK11 TIMD4 TINAGL1 TNFRSF10A TNFRSF13B TNFSF13B TNNI3 VEGFA VMO1 VWA1 FCN2 LEFTY2 SCLY SIT1 WISP2 WNT9A IGFBP4 IL10RB LAIR1 LCN2 LILRB4 LTBR MB MDK MMP10 NECTIN2 NECTIN4 NOS1 NPDC1 OSMR CTSD SIAE SMPD1 PODXL2 HS6ST1 ACAN INHBC K R T5 GSTP1 ANXA10 PLA2G10 IL17D DPT NEFL WNT9A WISP2 SMOC2 CHRDL1 KLK4 G FAP MMP12 MMP7 DTX3 SCARF2 SPON1 FAS NECTIN4 PTGDS CD27 RE LT IGFBP4 PIK3IP1 COL6A3 HSPG2 COLEC12 GUCA2A CCN3 OGN FAM3C NBL1 IGFBP6 LEFTY2 OPTC MLN IGFBP1 NPPB MSLN CHIT1 NTF4 SCGN C R TAC1 CDH5 FCGR3B TNR FABP9 CD207 CA14 ADAMTS13 KDR LAMP2 MEGF9 EGFR WFIKKN1 GGT1 GALANT7 GZMA TCL1A LRRN1 ENPP5 MSTN IL2RB DUSP3 FLT3 pericyte gamma stellate t_cell endothelial alpha schwann beta mast macrophage epsilon delta ductal acinar SST GCG ANPEP TMEM52 DPEP1 PNLIPRP1 REG1B CPB1 CTRC PLA2G1B CPA2 CTRB2 CTRL CUZD1 PNLIPRP2 CTRB1 SERPINI2 CLPS CELA3B PRSS1 PNLIP PRSS2 CELA2A GNMT AMY2A REG3G REG1A PRSS3 SPINK1 AKR7A3 ERP27 REG3A GATM IL32 IL22RA1 AMY2B INS F Extended Data Figure 14 BAL uid AT2 Epithelial progenitors Common (> 3 cell types) S100A14 HOPX NNMT NFATC4 FAM189A2 NEDD9 PTGS2 TP53I3 PPA1 KIF1C TXNRD1 RPL12 UCHL1 PRDX4 S100A10 GSTA1 S100A14 FATE1 CHST4 SULT2B1 UBD GDA SHISA2 MB CAMK1D PTK6 YBX2 NFATC4 BCCIP SSRP1 S100A14 SULT2B1 GDA GBP6 TMPRSS11A ANXA8 LEMD1 NR1D1 PTK6 SHISA2 CHST4 IL22RA1 TXNRD1 GSTA1 ANXA8L1 GSTA1 GBP6 KIF3A MYCT1 TNNT3 IK GDA FABP6 HSPH1 DPY30 MB ELK3 ANXA8L1 CYB5R2 IL22RA1 RBP1 ANXA8L1 SULT1C2 COLGALT2 LDHB TP53I3 ZNF10 CBX5 NRIP3 ACY1 ZNF566 DIDO1 IK FAM162A SULT2B1 NR1D1 FABP6 TNFRSF10D ZNF10 TSNARE1 KMT5C LONP1 ARMC5 HRK DNAJB2 TSSC4 YBX2 RBM39 ANXA8 LGALS4 RBFOX2 MST1R RAB17 EZR PRKCZ EVPL GALNT3 FUT3 ENTPD3 ALDH1A1 CYB5A LAYN CHST6 SYT17 ACP5 VSIG4 FBP1 MSR1 FABP4 LRPAP1 CTSL LRP1 SCARB2 LTA4H BLVRB HNMT TNFRSF10B KYNU TYMP FGR CD300E DDAH1 AK1 ITGB6 SUSD2 IGSF3 BCAM LTBR LDLR CEACAM8 EPS8L2 PRDX1 ALDH3A1 TACSTD2 EPHA2 PLXNB2 ACTN4 PCDH1 LRIG1 NUDC DNPH1 ALDH1A1 SORD CASC4 OSMR TNFRSF12A CKAP4 MCFD2 CA12 SLC39A14 ENAH LXN PDGFRA IFNGR1 ACVRL1 TGM2 CRIP2 NPDC1 SEMA4C NOTCH3 ACTA2 TNFRSF11A NDRG1 LAYN SNCG CD74 LAP3 LILRB4 TPP1 CLEC5A CTSC GUSB HAVCR2 BRK1 FKBP5 ADA VNN2 CLEC4D NADK S100A4 TNFRSF14 FMNL1 SAMD9L LBR CA2 DCXR SHMT1 LGALS4 EZR LHPP TNFRSF10A NDUFS6 SRP14 RRM2 CRELD2 TXNDC15 TXNDC5 THOP1 NOS3 HGF MB CDH2 CD274 IL18R1 RBKS IL5RA GALNT10 BTN3A2 ACY1 EDA2R SETMAR BLMH TBC1D17 SCLY WARS Intracellular severity-associated proteins at day 0 CDH2 TNNI3 MB ACTA2 FKBP5 VSIG4 KYNU MSR1 FABP4 NOTCH3 DDAH1 ACTN4 ENAH NOS1 CD274 ITGB6 RBP2 RBKS LHPP CKAP4 THOP1 LRPAP1 DNPH1 FABP2 SCARB2 TXNDC15 MCFD2 SETMAR TBC1D17 NUDC LGALS4 LTA4H BLMH LBR SEMA4C GUSB EPS8L2 IGSF3 SULT2A1 SCLY ACY1 IDI2 CA2 BRK1 PKLR ALDH3A1 CRELD2 FABP1 TXNDC5 CLEC4D CLEC5A RRM2 IL5RA CDHR2 SORD SUSD2 EDA2R PHOSPHO1 TACSTD2 DCXR GPR37 CASC4 IFNGR1 LAYN BCAM PCDH1 NPDC1 TNFRSF10A PRDX1 S100A4 EZR HGF EPHA2 SNCG TPP1 VNN2 FBP1 ACP5 PLXNB2 LTBR TNFRSF14 ACVRL1 SAMD9L LAP3 CRIP2 SRP14 AK1 NDUFS6 TNFRSF12A TGM2 ADA GALNT10 PDGFRA LXN RBP5 NADK CTSL NDRG1 TNFRSF10B CD74 NOS3 WARS ALDH1A1 TYMP BLVRB HAVCR2 FGR FMNL1 CD300E TNFRSF11A LILRB4 BTN3A2 IL18R1 LRP1 HNMT SHMT1 LRIG1 CA12 CEACAM8 OSMR SLC39A14 LDLR THBS2 FABP1 RBP5 NUDC FBP1 ALDH1A1 NDUFS6 DNPH1 PRDX1 LDLR CDH2 LRP1 SLC39A14 SHMT1 SORD BLVRB CA2 IFNGR1 TPP1 LILRB4 FKBP5 HNMT SCARB2 VSIG4 MSR1 FGR FMNL1 BTN3A2 CTSC HAVCR2 S100A4 LRIG1 CDHR2 PCDH1 CASC4 TNFRSF10B PKLR GPR37 ACY1 LHPP GUSB NADK PLXNB2 EPS8L2 DDAH1 MCFD2 THOP1 BCAM KYNU LAP3 RBKS BRK1 AK1 LBR PHOSPHO1 CD300E LTA4H TYMP ADA SAMD9L VNN2 TNFRSF14 GALNT10 EZR LRPAP1 IL5RA TXNDC15 CKAP4 CRELD2 TXNDC5 SRP14 SUSD2 NOTCH3 NDRG1 NOS1 ACVRL1 LTBR EPHA2 ACTN4 ENAH CLEC4D CLEC5A FABP4 TNFRSF11A TNFRSF10A CA12 MB ALDH3A1 SETMAR ITGB6 SCLY TBC1D17 IL18R1 CD274 SEMA4C BLMH LAYN TNNI3 EDA2R IGSF3 WARS OSMR NOS3 RRM2 CD74 CTSL ACP5 TGM2 LXN NPDC1 SNCG CRIP2 LGALS4 TNFRSF12A TACSTD2 PDGFRA HGF ACTA2 THBS2 ACE2 TMPRSS2 CCL2 CCL7 TIMP1 SPP1 CXCL10 CXCL9 NAMPT CD274 CXCL8 TNFSF12 RSPO3 LRPAP1 LGALS9 IL15 IL6 CCL17 HGF LTBR PVR TNFSF13 CD74 CXCL13 FASLG CEACAM1 SEMA4D OSM CSF1 CCL20 TNFRSF14 SEMA4C CX3CL1 TGFA SPINT1 GDF15 TNC LIF TNFRSF13B CXCR5 CSF1R ITGA5 HAVCR2 SORT1 CD72 IL6R IL15RA ITGAV KREMEN1 ITGA9 ITGB3 CCR3 KREMEN2 FZD8 CD4 ITGB1 TNFRSF17 TGFBR2 SORL1 CX3CR1 IL2RG CCR2 CXCR2 CXCR1 TNFSF14 CCR6 BTLA IL6ST CD226 PDCD1 FAS CCR4 S1PR1 IL2RA TIGIT IL2RB CD96 LAG3 CXCR3 ITGA4 OSMR MET LRP6 EGFR TNFRSF12A PLXNB2 PLXNB1 ACKR4 INSR LGR4 LIFR ERBB2 LRP5 ST14 Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Longitudinal analyses reveal immunological misfiring in severe COVID-19 An inflammatory cytokine signature predicts COVID-19 severity and survival Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans Factors associated with COVID-19-related death using OpenSAFELY Comprehensive mapping of immune perturbations associated with severe COVID-19 Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19 Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis Proteomic and Metabolomic Characterization of COVID-19 Patient Sera WHO R&D Blueprint -Novel Coronavirus, COVID-19 Therapeutic Trial Synopsis A single-cell atlas of the peripheral immune response in patients with severe COVID-19 Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis An inflammatory cytokine signature helps predict COVID-19 severity and death. medRxiv (2020) Chymotrypsin Reduces the Severity of Secretagogue-Induced Pancreatitis in Mice Carboxypeptidase E modulates intestinal immune homeostasis and protects against experimental colitis in mice Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI) Author Contributions Conceptualization: Filbin (M.R.F.), Mehta (A.M.), Hacohen (N.H.), Goldberg (M